Hormonal responses and future treatment of non‐insulin‐dependent diabetes mellitus (NIDDM)*
1993; Wiley; Volume: 234; Issue: 2 Linguagem: Inglês
10.1111/j.1365-2796.1993.tb00721.x
ISSN1365-2796
Autores Tópico(s)Metabolism, Diabetes, and Cancer
ResumoJournal of Internal MedicineVolume 234, Issue 2 p. 127-138 Hormonal responses and future treatment of non-insulin-dependent diabetes mellitus (NIDDM)* S. EFENDIC MD, Corresponding Author S. EFENDIC MD Department of Endocrinology, Karolinska Institute, Karolinska Hospital, Stockholm, SwedenDepartment of Endocrinology, Karolinska Hospital, S-104 01 Stockholm, Sweden.Search for more papers by this authorC.-G. ÖSTENSON, C.-G. ÖSTENSON Department of Endocrinology, Karolinska Institute, Karolinska Hospital, Stockholm, SwedenSearch for more papers by this author S. EFENDIC MD, Corresponding Author S. EFENDIC MD Department of Endocrinology, Karolinska Institute, Karolinska Hospital, Stockholm, SwedenDepartment of Endocrinology, Karolinska Hospital, S-104 01 Stockholm, Sweden.Search for more papers by this authorC.-G. ÖSTENSON, C.-G. ÖSTENSON Department of Endocrinology, Karolinska Institute, Karolinska Hospital, Stockholm, SwedenSearch for more papers by this author First published: August 1993 https://doi.org/10.1111/j.1365-2796.1993.tb00721.xCitations: 14 * This article is based on presentations of the authors at the Second Toronto-Stockholm Symposium ‘New Concepts in the Pathogenesis of NIDDM’, held in Stockholm, 13–16 September 1992. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157–75. 2 World Health Organization. World Health Organization Expert Committee: Second Report on Diabetes Mellitus. Technical Report Series No. 646. Geneva, Switzerland, 1980. 3 Efendic S., Luft R., Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 1984; 5: 395–409. 4 DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 317–68. 5 Cerasi E., Luft, R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Copenh) 1967; 55: 278–304. 6 Efendic S., Grill V., Luft R., Wajngot A. Low insulin response: a marker of prediabetes. Adv Exp Med Biol 1988; 246: 167–74. 7 Lillioja S., Mott DM, Howard BV, Bennett PH, Ykl-Järvinen H., Freymond D., Nyomba BL, Zurlo F., Swinburn B., Bogardus C. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988; 318: 1217–25. 8 Lillioja SJ, Nyomba BL, Saad MF, Ferraro R., Castillo C., Bennett PH, Bogardus C. Exaggerated early insulin release and insulin resistance in a diabetes prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab 1991; 73: 866–76. 9 Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607. 10 Luft R., Cerasi E., Hamberger CA. Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 1967; 56: 593–607. 11 Luft R., Cerasi E., Andersson B. Obesity as an additional factor in the pathogenesis of diabetes. Acta Endocrinol (Copenh) 1968; 59: 344–52. 12 Unger RH, Aquilar-Parada E., Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970; 49: 837–48. 13 Efendic S., Gutniak M., Grill V. Hormonal release in NIDDM. In: V. Grill, S. Efendic eds. Pathogenesis of Non-Insulin Dependent Diabetes Mellitus. New York: Raven Press, 1988; 271–84. 14 Grill V., Gutniak M., Roovete A., Efendic S. A stimulating effect of glucose on somatostatin release is impaired in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1984; 59: 293–7. 15 Johansson C., Wisen O., Efendic S., Uvnäs-Wallensten K. Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 1981; 22: 126–37. 16 Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231–45. 17 Gutniak M., Karlander SG, Efendic S. Glyburide decreases insulin requirement, increases β-cell response to mixed meal, and does not affect insulin sensitivity. Effects of short-and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 1987; 10: 545–54. 18 Kolterman OG, Gray RS, Shapiro G., Scarlett JA, Griffin J., Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes 1984; 33: 346–54. 19 Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1986; 314: 1280–6. 20 Mandarino LJ, Gerich JE. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care 1984; 7: 89–99. 21 Best JD, Judzewitsch RG, Pfeiffer MA, Beard JC, Halter JB, Porte D. Jr. The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin dependent diabetes. Diabetes 1982; 31: 333–8. 22 Efendic S., Kindmark H., Berggren P-O. Mechanisms involved in the regulation of the insulin secretory process. J Intern Med 1991; 229 (Suppl. 2): 9–22. 23 Bailey CJ. Metformin revisited; its actions and indications for use. Diabet Med 1988; 5: 315–20. 24 Efendic S., Wajngot A., Cerasi E., Luft R. Insulin release, insulin sensitivity and glucose intolerance. Proc Natl Acad Sci USA 1980; 77: 7425–9. 25 Gutniak M., Grill V., Efendic S. Effect of composition of mixed meals low- versus high-carbohydrate content on insulin, glucagon, somatostatin release in healthy humans and in patients with NIDDM. Diabetes Care 1986; 9: 244–9. 26 Gutniak M., Grill V., Efendic S. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action. J Clin Endocrinol Metab 1986; 62: 77–83. 27 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954–62. 28 Porte D. Jr β-cells in type II diabetes mellitus. Diabetes 1991; 40: 166–80. 29 Pigon J., Waldelöf K., Östenson C-G. Arginine-induced insulin secretion is impaired in type 2 diabetic patients compared with controls with identical glycaemia and insulinaemia. Diabetologia 1991; 34 (Suppl. 2): A108. 30 Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN. Insulin deficiency in noninsulin-dependent diabetes. Lancet 1989; i: 293–5. 31 Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D. Disproportionate elevation of immunoreactive pro-insulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698–702. 32 Westman S. Development of the obese-hyperglycemic syndrome in mice. Diabetologia 1968; 4: 141–9. 33 Khan A., Chandramouli V., Östenson C-G, Ahren B., Schumann WC, Löw H., Landau BR, Efendic S. Evidence for the presence of glucose cycling in pancreatic islets of the ob/ob mouse. J. Biol Chem 1989; 264: 9732–3. 34 Khan A., Chandramouli V., Östenson C-G, Berggren P-O, Löw H., Landau BR, Efendic S. Glucose cycling is markedly enhanced in pancreatic islets of obese hyperglycemic mice. Endocrinology 1990; 126: 2413–6. 35 Katz J., Rognstad R. Futile cycles in the metabolism of glucose. Curr Top Cell Regul 1976; 10: 237–89. 36 Malaisse WJ, Hutton JC, Kawazu S., Herchuelz A., Valverde I., Sener A. The stimulus-secretion coupling of glucose induced insulin release: the links between metabolism and cationic events. Diabetologia 1979; 16: 321–41. 37 Kakei M., Kelly RP, Ashcroft SJH, Ashcroft FM. The ATP-sensitivity of K+ channels in rat pancreatic β-cells is modulated by ADP. FEBS Lett 1986; 208: 63–6. 38 Goto Y., Suzuki K., Sasaki M., Ono T., Abe S. GK rat as a model of non-obese, noninsulin-dependent diabetes. Selective breeding over 35 generations. In: E. Shafrir, AE. Renold eds. Frontiers in Diabetes Research. Lessons from Animal Diabetes II. London: John Libbey, 1988; 301–3. 39 Östenson C-G, Khan A., Abdel-Halim SM, Guenifi A., Suzuki K., Goto Y., Efendic S. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993; 36: 3–8. 40 Abdel-Halim SM, Guenifi A., Efendic S., Östenson C-G. Both somatostatin and insulin responses to glucose are impaired in the perfused pancreas of spontaneously non-insulin-dependent diabetic GK rats. Acta Physiol Scand 1993; 148: 219–26. 41 Nolte LA, Martin IK, Abdel-Halim SM Guenifi A., Östenson C-G, Wallberg-Henriksson H. Effect of elevated blood glucose on insulin-stimulated glucose transport in rat muscle. Diabetologia 1992; 35 (Suppl. 1): A80. 42 Ahren B., Östenson C-G, Efendic S. Other islet peptides. In: E. Samols ed. The Endocrine Pancreas. New York: Raven Press, 1991; 153–73. 43 Berggren P-O, Rorsman P., Efendic S., Östenson C-G, Flatt P., Nilsson T., Arkhammar P., Juntti-Berggren L. Mechanisms of action of entero-insular hormones, islet peptides and neural input on the insulin secretory process. In: P. Flatt ed. Nutrient Regulation of Insulin Secretion. London: Portland Press, 1992; 289–318. 44 Dunning BE, Ahren B., Veith RC, Böttcher G., Sundler F., Taborsky GJ. Galanin a novel pancreatic neuropeptide. Am J Physiol 1986; 251: E127–33. 45 Dunning BE, Taborsky GJ Jr. Galanin: a sympathetic neuro-transmitter in the endocrine pancreas Diabetes 1988; 37: 1157–62. 46 Bauer FE, Ginsberg L., Venetikou M., MacKay DJ, Burrin JM, Bloom SR. Growth hormone release in man induced by galanin, a new hypothalamic peptide. Lancet 1986; ii: 192–5. 47 Westermark P., Wernstedt C., O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 1987; 127: 414–7. 48 Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky Jr GJ, Porte D. Jr. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 1990; 39: 634–8. 49 Porte D. Jr, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet β-cells dysfunction Diabetes 1989; 38: 1333–6. 50 Ohsawa H., Kanatsuka A., Yamaguchi T., Makino H., Yoshida S. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 1989; 160: 961–7. 51 Leighton B., Cooper GJS. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632–5. 52 Sanke T., Hanabusa T., Nakano Y., Oki C., Okai K., Nishimura S., Kondo M., Nanjo K. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1991; 34: 129–32. 53 Ravazzola M., Efendic S., Östenson C-G, Tatemoto K., Hutton JC, Orci L. Localization of pancreastatin immunoreactivity in porcine endocrine cells. Endocrinology 1988; 123: 227–9. 54 Östenson C-G, Efendic S., Holst JJ. Pancreastatin -like immuno-reactivity and insulin are released in parallel from the perfused porcine pancreas. Endocrinology 1989; 224: 2986–90. 55 Tatemoto K., Efendic S., Mutt V., Makk G., Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476–8. 56 Efendic S. Tatemoto K, Mutt V, Quan C, Chang D, Östenson C-G. Pancreastatin and islet hormone release. Proc Natl Acad Scie USA 1987; 84: 7257–60. 57 Östenson C-G, Sandler S., Efendic S. Effects of porcine pancreastatin on secretion and biosynthesis of insulin, and glucose oxidation of isolated rat pancreatic islets. Pancreas 1989; 45: 441–6. 58 Funakoshi A., Tateishi K., Shinozaki H., Matsumoto M., Wakasugi H. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin dependent diabetes mellitus (NIDDM). Regul Peptides 1990; 30: 159–64. 59 Leahy JL, Cooper HE, Weir GC. Impaired insulin secretion associated with near normoglycaemia. Study in normal rats with 96-h in vivo glucose infusions. Diabetes 1987; 36: 459–64. 60 Svensson C., Hellerström C. Long-term effects of a high glucose concentration in vitro on the oxidative metabolism and insulin production of isolated rat pancreatic islets. Metabolism 1991; 40: 513–8. 61 Leahy JL, Bonner-Weir S., Weir GC. Abnormal insulin secretion in a streptozotocin model of diabetes. Effects of insulin treatment. Diabetes 1985; 34: 660–5. 62 Blondel O., Bailbe D., Portha B. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism 1990; 39: 787–93. 63 Vague P., Moulin J-P. The defective glucose sensitivity of the β-cell in insulin dependent diabetes: improvement after twenty hours of normoglycaemia. Metabolism 1982; 31: 139–42. 64 Kosaka K., Kuzuya T., Akanuma Y., Hagura R. Increase in insulin response after treatment of overt maturity onset diabetes mellitus is independent of the mode of treatment. Diabetologia 1980; 18: 23–8. 65 Garvey WT, Olefsky JM, Griffin J., Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes melitus. Diabetes 1985; 34: 222–34. 66 Rahier J., Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983; 24: 366–71. 67 Stefan Y., Orci L., Malaisse-Lagae F., Perrelet A., Patel Y., Unger RH. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 1982; 31: 694–700. 68 Klöppel G., Löhr M., Habich K., Oberholzer M., Heitz PV. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Path Res 1985; 4: 110–25. 69 Clark A., Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GHS, Holman RR, Turner RC. Islet amyloid, increased A-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Research 1988; 9: 151–9. 70 Unger RH, Orci L. Glucagon in diabetes mellitus. In: PJ. Lefevre ed. Glucagon II. Berlin/Heidelberg/New York/Tokyo: Springer-Verlag, 1983; 431–50. 71 Kawamori R., Shichiri M., Yamasaki Y., Abe H. Perfect normalization of excessive glucagon response to intravenous arginine in human diabetes mellitus with the artificial beta cell. Diabetes 1980; 29: 762–5. 72 Raskin P., Fujita Y., Unger RH. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and non-diabetics. J Clin Invest 1975; 56: 1132–8. 73 Gutniak M., Grill V., Wiechel K-L, Efendic S. Basal and meal-induced somatostatin-like immunoreactivity in healthy subjects and in IDDM and totally pancreatectomized patients. Effects of acute blood glucose normalization. Diabetes 1987; 36: 802–7. 74 Gutniak M., Grill V., Roovete A., Efendic S. Impaired somatostatin response to orally administered glucose in NIDDM patients entails both somatostatin-28 and −14 and is associated with deranged metabolic control. Acta Endocrinol 1989; 121: 322–6. 75 Hermansen KH, Orskov FH, Christensen SE. Streptozotocin diabetes: a glucoreceptor dysfunction affecting D-cells as well as beta- and alpha-cells. Diabetologia 1979; 17: 385–9. 76 Grill V., Efendic S. Abnormal D-cells secretion in alloxan-diabetes: influence by drug and aberrant metabolism. Am J Physiol 1984; 246: E483–92. 77 Östenson C-G, Efendic S., Grill V. Abnormal regulation by glucose of somatostatin secretion in the perfused pancreas of NIDDM rats. Pancreas 1990; 5: 347–53. 78 Krejs G., Browne R., Raskin P. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes. Gastroenterology 1980; 78: 26–31. 79 Efendic S., Luft R. Somatostatin. A classical hormone, a locally active polypeptide and a neurotransmitter. Ann Clin Res 1980; 12: 87–94. 80 Harris AG, Gutniak MK, Efendic S. Somatostatin markedly decreases meal-related insulin requirements in IDDM and NIDDM. Diabetes 1991; 40: 74A. 81 Sten-Linder M., Wedell A., Iselius L., Efendic S., Luft R., Luthman H. DNA polymorphisms in the human tyrosine hydroxylase/insulin/insulin-like growth factor II chromosomal region in relation to glucose and insulin responses. Diabetologia 1993; 36: 25–32. 82 Froguel P., Vaxillaire M., Sun F., Velho G., Zouali H., Butel MO et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356: 162–4. 83 Iselius L., Lindsten J., Morton NE, Efendic S., Cerasi E., Haegermark A., Luft R. Genetic regulation of the kinetics of glucose-induced insulin release in man. Clin Genetics 1985; 28: 8–15. 84 Östenson C-G, Pigon J., Pye S., Radziuk J., Efendic S. Different mechanisms of low insulin response in prediabetic and endurance-trained subjects. Diabetologia 1992; 35 (Suppl. 1): A108. 85 Grill V., Pigon J., Hartling SG, Binder C., Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 1990; 39: 251–8. 86 Wajngot A., Giacca A., Grill V., Vranic M., Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. Proc Natl Acad Sci USA 1992; 89: 6035–9. 87 Kosaka K., Hagura R., Kuzuya T. Insulin response in equivocal and definite diabetes, with special references to subject who had mild glucose intolerance but later developed definite diabetes. Diabetes 1977; 26: 944–52. 88 O'Rahilly SP, Nugent Z., Rudenski AS, Hosker JP, Burnett MA, Darling P., Turner R. Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familiar type 2 diabetes. Lancet 1986; ii: 360–64. 89 Pimenta W., Mitrakou A., Capani F., Yki-Järvinen H., Gerich J. Beta-cell dysfunction with normal insulin sensitivity in glucose tolerant first-degree relatives of Caucasian NIDDM patients. Diabetes 1992; 41 (Suppl. 1): 143A. 90 Rull J., Conn JW, Floyd JC Jr, Fajans SS. Levels of plasma insulin during cortisone glucose tolerance tests in ‘nondiabetic’ relatives of diabetic patients. Implications of diminished insulin secretory reserve in subclinical diabetes. Diabetes 1970; 19: 1–10. 91 Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75–85. 92 Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologica 1992; 35: 701–11. 93 Gutniak M., Orskov C., Holst JJ, Ahren B., Efendic S. Anti-diabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 32: 1316–22. 94 Orskov C., Jeppesen J., Madsbad S., Holst, JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415–23. 95 Novak U., Wilks A., Buell G., McEwen S. Identical mRNA for pre-proglucagon in pancreas and gut. Eur J Biochem 1987; 164: 553–8. 96 Hansen IL, Cryer PE, Rizza RA. Comparison of insulin-mediated and glucose-mediated glucose disposal in patients with insulin-dependent diabetes mellitus and in nondiabetic subjects. Diabetes 1985; 34: 751–5. Citing Literature Volume234, Issue2August 1993Pages 127-138 ReferencesRelatedInformation
Referência(s)